“MAS is not as rare as we once thought. It could be seen in autoimmune diseases, such as systemic onset juvenile arthritis or lupus, or in such settings as infection,” says Dr. Stevens. “When rheumatologists see MAS, they know how to recognize and treat it—and you can turn this [disease] around with the right treatment. We’ll have the top three experts at this session, and the focus is the role of treatment selection—picking the right treatment for the individual patient.”
Juvenile Localized Scleroderma: Does This Child Have Active Disease?
Tuesday, Nov. 12, 11 a.m.–12 p.m.
Dermatologists may refer patients to rheumatologists who have juvenile localized scleroderma, which can cause deep scarring. “It’s very invasive, and can begin on the leg and then go into the brain,” Dr. Stevens says. “It’s a very slow disease, and it’s challenging to know if there is active scarring or if it’s more quiet. Do these patients need more immunosuppression or less?”
During the session, these important clinical questions, as well as the most recent data on ultrasound and thermography, will be discussed by experts in the field.
Join Us at the Annual Meeting
The 2019 ACR/ARP Annual Meeting, Nov. 8–13, in Atlanta is your gateway to global rheumatology education. View the Online Program to find out more about the opportunities for professional development and networking, and obtain firsthand access to the latest rheumatology research and clinical applications. Register now, and don’t miss out.